Expression of multidrug resistance-related transporters in human breast carcinoma

被引:82
作者
Kanzaki, A
Toi, M
Nakayama, K
Bando, H
Mutoh, M
Uchida, T
Fukumoto, M
Takebayashi, Y
机构
[1] Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Tokyo Metropolitan Komagome Hosp, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan
[3] Toray Industries Ltd, Pharmaceut Res Labs, Kanagawa 2488555, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 2001年 / 92卷 / 04期
关键词
MDR; BCRP; breast carcinoma;
D O I
10.1111/j.1349-7006.2001.tb01115.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression levels of mRNA for multidrug resistance 1 (MDR1) gene, multidrug resistance protein 1 (MRP1), lung resistance-related protein (LRP) and breast cancer resistance protein (BCRP), which confer multidrug resistance in vitro, were examined in 43 untreated breast carcinoma patients, of whom 38 subsequently received doxorubicin-based chemotherapy after surgery, in order to elucidate the roles of these genes in drug resistance in vivo, The mRNA levels were determined using a semi-quantitative reverse-transcription polymerase chain reaction method in breast carcinoma tissues including at least 80% carcinoma cells, The expression level of BCRP gene was low and did not vary markedly in comparison with that of MDR1, MRP1 or LRP gene. The expressions of MDR1 and MRP1 genes were correlated with each other, but the expression of BCRP or LRP gene did not correlate with that of other genes, These four gene expressions were independent of age, TNM categories and the status of progesterone or estrogen receptor, The expression levels of these four genes were not related to the relapse or prognosis of the 38 patients treated with doxorubicin-based chemotherapy. P-glycoprotein (P-gp)MDR1, MRP1 and LRP may play more important roles than BCRP in chemotherapy of human breast carcinoma.
引用
收藏
页码:452 / 458
页数:7
相关论文
共 36 条
  • [1] Allen JD, 1999, CANCER RES, V59, P4237
  • [2] Allikmets R, 1998, CANCER RES, V58, P5337
  • [3] GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN
    ALVAREZ, M
    PAULL, K
    MONKS, A
    HOSE, C
    LEE, JS
    WEINSTEIN, J
    GREVER, M
    BATES, S
    FOJO, T
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) : 2205 - 2214
  • [4] Using the national cancer institute anticancer drug screen to assess the effect of mrp expression on drug sensitivity profiles
    Alvarez, M
    Robey, R
    Sandor, V
    Nishiyama, K
    Matsumoto, Y
    Paull, K
    Bates, S
    Fojo, T
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (05) : 802 - 814
  • [5] Beck WT, 1996, CANCER RES, V56, P3010
  • [6] Brangi M, 1999, CANCER RES, V59, P5938
  • [7] QUANTITATIVE IMMUNOCYTOCHEMICAL ASSAYS OF P-GLYCOPROTEIN IN BREAST CARCINOMAS - CORRELATION TO MESSENGER-RNA EXPRESSION AND TO IMMUNOHISTOCHEMICAL PROGNOSTIC INDICATORS
    CHARPIN, C
    VIELH, P
    DUFFAUD, F
    DEVICTOR, B
    ANDRAC, L
    LAVAUT, MN
    ALLASIA, C
    HORSCHOWSKI, N
    PIANA, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20): : 1539 - 1545
  • [8] Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO
  • [9] 2-X
  • [10] MULTIDRUG RESISTANCE ASSOCIATED PROTEIN - SEQUENCE CORRECTION
    COLE, SPC
    DEELEY, RG
    [J]. SCIENCE, 1993, 260 (5110) : 879 - 879